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Abstract 
A 64-year-old man with a pulmonary transplant developed diffuse verrucae vulgares of 
the neck. After the failure of multiple cryotherapy treatments, 3 sessions of 
photodynamic therapy resulted in rapid therapeutic clinical success. This moderately 
painful and well-tolerated treatment is reproducible and can be very useful in treating 
papillomavirus infections in the immunosuppressed patient. 
 
Case Report 
We report the case of a 64-year-old man, who had been under immunosuppressive treatment for 
many years after a pulmonary transplant, who presented with diffuse viral warts on the neck and chin 
that had been present for 11 months (fig. 1). Cryotherapy sessions were conducted over the course of 9 
months without success but with increasing intolerance to the related pain. Imiquimod had not been 
suggested due to its theoretical contraindications relating to the risk of a graft rejection and a graft-
versus-host disease. 
A photodynamic therapy (PDT) test session was carried out on the most prominent warts in the 
submental region, with a very clear improvement after 1 week (fig. 2). Two more sessions were 
conducted within a 10-day interval, using 2 fields of light each time, thus covering the entire surface of 
the neck (right and left sides). Three hours after an application of 5-aminolevulinic acid (Metvix) 
under an occlusive and opaque dressing, a red light of 634 nm was delivered, with a 37 J/cm
2 light 
intensity for the duration of 9 min. A spray bottle filled with spring water, in combination with an 
integrated cooling fan, was used to decrease pain during illumination. Treatment was relatively well 
tolerated. The painful sensation lasted 1–2 h after illumination, whereas erythema and swelling 
decreased after 2–3 days. Side effects were well tolerated and were considered minor by the patient. 
Complete healing was archieved after 8 days.  
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A fast and marked improvement was noted after only 2 sessions of PDT. A third session resulted in 
complete clearance (fig. 3). No recurrence was noted 1 year after the last session of treatment. 
Discussion 
Viral wart treatments include local keratolytic application, topical retinoids, 
cryotherapy, intralesional injection of bleomycin, imiquimod, laser CO2, pulsed dye laser 
and intralesional immunotherapy [1]. The benefit-risk ratio in organ-transplanted 
patients is currently being evaluated [2]. PDT has proven to be successful in the treatment 
of actinic keratosis and basocellular carcinoma. At present, new indications are emerging, 
including verrucae vulgares. 
Several studies show that protoporphyrin IX accumulation after 5-aminolevulinic acid 
application is not specific to tumour cells [3]. HPV-infected cells also accumulate 
protoporphyrin IX in a specific manner, as compared to the surrounding healthy cells [4, 
5], as demonstrated by in vivo fluorescence spectroscopy [6]. PDT therapeutic effects are 
due to anti-inflammatory and anti-proliferative properties activated through the release of 
cytotoxic radicals that destroy keratinocytes via selective apoptosis [7]. 
Numerous clinical studies have demonstrated the efficiency of PDT in the treatment of 
viral warts of the hands [8] and feet, (recalcitrant [9–13] or not), including periungual 
warts. Several studies have shown that PDT is efficient in treating plane warts [14, 15], 
including those on the face [16]. Ohtsuki et al. [17] treated verrucae vulgares on the hands 
and feet with a clear clinical improvement in 68.3% of the patients. This improvement 
was confirmed by a placebo-controlled study led by Bastuji-Garin et al. [18]. In addition, 
Wang et al. [19] successfully treated 42% of recalcitrant viral warts, and Chong and Kang 
[20] reported complete healing of recalcitrant foot verrucae vulgares after only 3 PDT 
sessions. Schroeter et al. [21] treated periungual warts with full clinical success in 90% of 
patients after a mean of 4.7 sessions. Some authors suggested the use of a keratolytic pre-
treatment (urea 10%, salicylic acid 10%, for 1 week) to enhance the treatment’s efficiency, 
with complete healing in 75% of viral warts [6]. In the immunosuppressed subject, 
Granel-Brocard et al. [22] reported the therapeutic effect of PDT on recalcitrant warts. 
The advantages of PDT are numerous. It is a safe, noninvasive technique, which yields 
effective therapeutic results in multiple series of patients [17, 23]. The risk of secondary 
infection after PDT is insignificant, and the cosmetic results are excellent [7]. The 
technique is particularly interesting in slow-healing subjects and acts selectively, allowing 
healthy surrounding skin to remain intact and functional [24]. The use of one or several 
fields of light enables treatment of many lesions at the same time, thus limiting the risk of 
wart spread and recurrence between sessions. The drawbacks are pain and local side 
effects such as erythema and swelling, which is generally mild and well tolerated (table 1, 
table 2, table 3). 
Immunosuppressed patients often present with extensive viral warts. Controlling the 
spead of these warts is of great importance because they can potentially be a source of 
neoplasia [25]. Our case report shows that PDT can be very efficient in the treatment of 
verrucae vulgares in immunosuppressed organ-transplanted patients. The technique is 
easy to implement, resulting in minimal side effects and reproducible results.   
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We think that PDT should be considered as a gold standard in the treatment of facial 
verrucae vulgares in immunodepressed patients. 
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Table 1. Efficiency of PDT: patient characteristics, treatment and localisation 
Sex   Study
a 
 
0Patients 
0(n) 
Age 
(years)  F M   
Treatments Immunologic 
status 
Level of 
evidence 
Localisation
Lu [15]  018 18–41  13  05  RPW  NS  D  1 
Ohtsuki [17]  006 22–45  02  04  RVV  NS  D  2,  3 
Morton [24]  012 20–45  08  04  RVV  NS  D  4 
Lin [16]  003 15–25  02  01  RPW  NS  D  1 
Granel-
Brocard [22] 
 
001 
 
54 
 
01 
 
00 
  
RVV 
 
ID 
 
D 
 
3 
Wang [19]  012 18–70  02 10  RVV  IC  D  2,  3 
Schroeter [21]  020 10–55  17  03  RVV,  NPT NS  D  4 
Schroeter [12]  031  06–74 18  13    RVV  NS  D  3 
Mizuki [14]  001 13 00  01  RPW  NS  D  1 
Fabbrocini [6] 067 18–40  31  36    RVV  NS  C  3 
Stender [9]  045 20–84  26  19    RVV  IC  C  2,  3 
Stender [13]  030  22–74  16  14    RVV  3 ID  D  2, 3 
Stender [10]  052  16–79  42  20    RVV, RPW  5 ID  D  1, 2, 3, 5 
Smetana [5]  001 NS NS  NS    NS  ID  D  2 
Stender [11]  004  NS  NS  NS    RVV  NS  D  2, 3, 6, 7 
Ammann [23] 006 21–31  02  04  RVV  NS  D  2 
F = Female; M = male; NS = not specified; RVV = recalcitrant verrucae vulgares; RPW = recalcitrant 
plane warts; ID = immunodeficient; IC = immunocompetent; NPT = no previous treatment. 1 = Face; 2 = 
hand; 3 = foot; 4 = periungual; 5 = arm; 6 = knee; 7 = heel. 
a First author [reference]. 
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Table 2. Efficiency of PDT: session specifics 
Study
a 
 
Photosensitizer  0Occlusion 
0(h) 
Session  
(n) 
0Interval 
Lu [15]  ALA 10%  04  02–3  02 w 
Ohtsuki [17]  ALA 20%  05 10  02–3 w 
Lin [16]  ALA 20%  03  04–5  01 w 
Granel-Brocard [22]  MAL  03–4  02  02 m 
Wang [19]  ALA 20%  04  04  02 w 
Schroeter [21]  ALA 20%  03–6  01–13  02 w 
Schroeter [12]  ALA 20%  04–8  01–7  0NS 
Mizuki [14]  ALA 20%  06  02  0NS 
Fabbrocini [6]  ALA 20% versus PLC  05  03  01 w 
Stender [9]  ALA 20% versus PLC  04  06  01–2 w 
Stender [13]  ALA 20%  05  01–3  010 d 
Stender [10]  ALA 20%  04–5  03  01 w 
Smetana [5]  ALA 20%  04  01  
Stender [11]  ALA 20%  12  02–3  0NS 
Ammann [23]  ALA 20%  05–6  01  
MAL = Methyl-aminolevulinic; ALA = aminolevulinic acid; PLC = placebo cream; w = week; m = 
month; d = day. 
a First author [reference]. 
 
 
Table 3. Efficiency of PDT: response to treatment 
Study
a 
 
Light source  Cure rate  0Follow-
0up 
Lu [15]  Laser 635 nm  CR: 17 persons  06 m 
Ohtsuki [17]  RL 633 nm  PR: 68.3%  04 w 
Lin [16]  RL 633 nm  CR: 100%   01–3 m 
Granel- 
Brocard [22] 
 
RL 570–670 nm 
 
CR: 100%  
 
05 m 
Wang [19]  RL 590–700 nm  CR: 5 persons  08–16 m 
Schroeter [21]  RL 580–720 nm  CR: 90%  05.9 m 
Schroeter [12]  RL 580–720 nm  CR: 88%  03 m 
Mizuki [14]  Metal Halide Lamp 630–700 nm  CR: 100%  05 m 
Fabbrocini [6]  Tungsten lamp, 630 nm  CR: 75% under ALA-PDT; 22.8% under 
PLC-PDT 
022 m 
Stender [9]  RL 590–700 nm  CR: 100% under ALA-PDT; 71% under 
PLC-PDT 
018 w 
Stender [13]  Halogen lamp  CR: 73%  012 m 
Stender [10]  White light from slide projector  CR: 58%; ID: 1 person  03–17 m 
Smetana [5]  Xenon lamp, RL 590–700 nm  Dramatic clearance  02 y 
Stender [11]  Unfiltered lamp  CR: 100%  06 w to  
01 y 
Ammann [23]  Visible light from slide projector  CR: 1 person  02 m 
PDL = Pulsed dye laser; CR = complete response; PR = partial response; RL = red light; IPL = intense 
pulsed light; NS = not specified; MoW = mosaic warts; MyW = myrmecia warts; VIS = visible light; 
wIRA = waterfiltered infrared A; ALA = aminolevulinic acid; PLC = placebo cream; ID = 
immunodeficient; m = months; w = weeks; y = years. 
a First author [reference]. 
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Fig. 1. Viral warts of the neck in a pulmonary transplanted patient under immunosuppressive 
treatment. 
 
 
 
Fig. 2. Clinical image after healing of the test area. 
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Fig. 3. Complete healing of the warts after three sessions of PDT. 
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